Study of Great Dosage Somatostatin Analogue in Reducing Hepatocellar Cancer

Objective To look for a reasonable and effective therapy of great dosage somatostatin analogue,SSTA against hepatitis B with α-fetal globin protein (AFP) elevation, hepatic- fibrosis and reduce ratio of hepaticellar cancer(HCC) occurrence. Methods 29 patients of chronic active hepatitis B with AFP elevation(AFP 200ng/ml,above 3 months) were divided into 2 groups in random. 12 patiens of SSTA treatment group were given basic therapy medicine and great dose of somatostatin analogue 250μg/d, bid, hypodermic injection), the other 17 patients of basic treatment group were given basic medicine (include Ganlixin ,Kusengjian ,etc). The course of treatment was continued for 30 days. After sera test of IGF(insulin-like growth factor) AFP , type IV collagen(IV-C), procollagen type III (PCⅢ) per 2 month for half one year, the data were analyzed by statistics. Results There were obvious difference between 2 groups in IGF, AFP(P0.01) ,except for type IV collagen(IV-C), procollagen type III (PCⅢ)(P0.05). Conclusion feedback treatment with great dosage of SSTA may amend hepatic function, reduce AFP and IGF, but for index of hepatic- fibrosis, and at last, it may be benefit for reduce HCC occurrences.